Dynamic Load Balancing Algorithms For Cloud Computing

In cloud computing, the load balancing is one of the major requirment. Load is nothing but the of the amount of work that a system performs. Load can be classified as CPU load, memory size and network load. Load balancing is the process of dividing the task among various nodes of a distributed system to improve both resource utilization and job response time. Also avoiding a situation where some of the nodes are heavily loaded and others are idle. Load balancing ensures that every node in the network having equal amount of work (as per their capacity) at any instant of time. In This paper we survey the existing load balancing algorithms for a cloud based environment. DOI: 10.17762/ijritcc2321-8169.150612

Robust and Reusable Fuzzy Extractors and their Application to Authentication from Iris Data

Fuzzy extractors (FE) are cryptographic primitives that establish a shared secret between two parties who have similar samples of a random source, and can communicate over a public channel. An example for this is that Alice has a stored biometric at a server and wants to have authenticated communication using a new reading of her biometric on her device. Reusability and robustness of FE, respectively, guarantee that security holds when FE is used with multiple samples, and the communication channel is tamperable. Fuzzy extractors have been studied in information theoretic and computational setting. Contributions of this paper are two-fold. First, we define a strongly robust and reusable FE that combines the strongest security requirements of FEs, and give three constructions. Construction 1 has computational security, and Constructions 2 and 3 provide information theoretic (IT) security, in our proposed model. Construction 1 provides a solution to the open question of Canetti et al. (Eurocrypt 2014), by achieving robustness and reusability (post-quantum) security in standard model for their construction. Constructions 2 and 3 offer a new approach to the construction of IT-secure FE. Construction 3 is the first robust and reusable FE with IT-security without assuming random oracle. Our robust FEs use a new IT-secure MAC with security against key-shift attack which is of independent interest. Our constructions are for structured sources which for Construction 1, matches Canetti et al.’s source. We then use our Construction 1 for biometric authentication using iris data. We use a widely used iris data set to find the system parameters of the construction for the data set, and implement it. We compare our implementation with an implementation of Canetti et al.’s reusable FE on the same data set, showing the cost of post-quantum security without using random oracle, and robustness in standard model

Facile fabrication of large area oriented conjugated polymer films by ribbon-shaped FTM and its implication on anisotropic charge transport

Facile fabrication of large area [20cm (L) × 2cm (W)] uniform and oriented thin films of a variety of conjugated polymers (CPs) with minimal material wastage has been successfully demonstrated using our newly developed ribbon-shaped floating film transfer method (FTM). Under identical film fabrication conditions of FTM like hydrophilic liquid substrate consisted of ethylene glycol and glycerol (3:1), the temperature of 60°C and polymer concentration 1% (w/w) in chloroform, order of molecular orientation was found to be PQT-C12 > F8T2 > NR-P3HT > PBTTT-C14 > PTB7. Depending on the nature of polymeric backbone, CPs exhibited different optical anisotropies in their oriented thin films, which was explained in terms of nature and rigidity of polymeric chains in the light of persistent length. Organic field effect transistors fabricated using these CPs exhibited clear p-type behaviour and anisotropic charge transport. Amongst various CPs used, PQT-C12 not only exhibited the highest optical anisotropy (DR = 5.1) but also highest anisotropic charge transport (μ|/μ⊥ = 7.1). Ribbon-shaped thin films of PQT-C12 prepared by slider based FTM exhibited best device performance with charge carrier mobility of 5.0 × 10−2 cm2/V and ON/OFF ratio of 106, when films were oriented parallel to the channel direction. Interestingly, a mobility of parallel oriented thin films prepared by FTM was about two orders of magnitude higher compared to the OFETs fabricated using conventional spin coating (6.7× 10−4 cm2/V)

2D positional profiling of orientation and thickness uniformity in the semiconducting polymers thin films

Harnessing the full potential of solution processable conjugated polymers (CPs) as active semiconductor elements lies in the facile thin film fabrication along with amicable control of molecular self-assembly and orientation. Probing the nature and uniformity of thin films are inevitable for fabrication of devices with high reproducibility. Herein, a new method for the fast and facile profiling of thickness and molecular orientation of large area thin films is being reported. Thin films of PBTTT-C14 fabricated by three different methods like floating film transfer method (FTM), friction transfer and spin coating were subjected to profiling of thickness and molecular orientation using 2D positional mapping system followed by fabrication of organic thin film transistors. In order to prove applicability of the mapping system on other CPs, oriented films of PQT-C12 were also prepared by FTM and optical anisotropy estimated by the mapping system (23.0) and conventional spectrophotometer (22.4) validates the performance of our positional mapping system. Spin-coated thin films of PBTTT-C14 subjected to positional profiling of the film uniformity revealed that films are non-uniform and there was a gradual increase in the thickness from center to the periphery

Tumor reversion: a dream or a reality.

Reversion of tumor to a normal differentiated cell once considered a dream is now at the brink of becoming a reality. Different layers of molecules/events such as microRNAs, transcription factors, alternative RNA splicing, post-transcriptional, post-translational modifications, availability of proteomics, genomics editing tools, and chemical biology approaches gave hope to manipulation of cancer cells reversion to a normal cell phenotype as evidences are subtle but definitive. Regardless of the advancement, there is a long way to go, as customized techniques are required to be fine-tuned with precision to attain more insights into tumor reversion. Tumor regression models using available genome-editing methods, followed by in vitro and in vivo proteomics profiling techniques show early evidence. This review summarizes tumor reversion developments, present issues, and unaddressed challenges that remained in the uncharted territory to modulate cellular machinery for tumor reversion towards therapeutic purposes successfully. Ongoing research reaffirms the potential promises of understanding the mechanism of tumor reversion and required refinement that is warranted in vitro and in vivo models of tumor reversion, and the potential translation of these into cancer therapy. Furthermore, therapeutic compounds were reported to induce phenotypic changes in cancer cells into normal cells, which will contribute in understanding the mechanism of tumor reversion. Altogether, the efforts collectively suggest that tumor reversion will likely reveal a new wave of therapeutic discoveries that will significantly impact clinical practice in cancer therapy

Role of Exosomes in Tumor Induced Neo-Angiogenesis

Exosomes are the nanovesicles, belonging to the type of extracellular vesicles (EVs), produced by normal as well as tumor cells and function as a mode in cell-to-cell communication. Tumor cells utilize various approach to communicate with neighboring cells for facilitating tumor invasion and progression, one of these approaches has been shown through the release of exosomes. Tumor-derived exosomes (TEX) have the ability to reprogram/modulate the activity of target cells due to their genetic and molecular cargo. Such exosomes target endothelial cells (among others) in the tumor microenvironment (TME) to promote angiogenesis which is an important element for solid tumor growth and metastasis. So, exosomes play a vital role in cancer invasiveness and progression by harboring various cargoes that could accelerate angiogenesis. Here first, we will present an overview of exosomes, their biology, and their role in different cancer models. Then, we will emphasis on exosomes derived from tumor cells as tumor angiogenesis mediators with a particular importance on the underlying mechanisms in various cancer origins. In the end, we will unveil the therapeutic potential of tumor derived exosomes as drug delivery vehicles against angiogenesis

Bronchiectasis in India:results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry

BACKGROUND: Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income and middle-income countries. We therefore aimed to describe the characteristics, severity of disease, microbiology, and treatment of patients with bronchiectasis in India. METHODS: The Indian bronchiectasis registry is a multicentre, prospective, observational cohort study. Adult patients ( 6518 years) with CT-confirmed bronchiectasis were enrolled from 31 centres across India. Patients with bronchiectasis due to cystic fibrosis or traction bronchiectasis associated with another respiratory disorder were excluded. Data were collected at baseline (recruitment) with follow-up visits taking place once per year. Comprehensive clinical data were collected through the European Multicentre Bronchiectasis Audit and Research Collaboration registry platform. Underlying aetiology of bronchiectasis, as well as treatment and risk factors for bronchiectasis were analysed in the Indian bronchiectasis registry. Comparisons of demographics were made with published European and US registries, and quality of care was benchmarked against the 2017 European Respiratory Society guidelines. FINDINGS: From June 1, 2015, to Sept 1, 2017, 2195 patients were enrolled. Marked differences were observed between India, Europe, and the USA. Patients in India were younger (median age 56 years [IQR 41-66] vs the European and US registries; p<0\ub70001]) and more likely to be men (1249 [56\ub79%] of 2195). Previous tuberculosis (780 [35\ub75%] of 2195) was the most frequent underlying cause of bronchiectasis and Pseudomonas aeruginosa was the most common organism in sputum culture (301 [13\ub77%]) in India. Risk factors for exacerbations included being of the male sex (adjusted incidence rate ratio 1\ub717, 95% CI 1\ub703-1\ub732; p=0\ub7015), P aeruginosa infection (1\ub729, 1\ub710-1\ub750; p=0\ub7001), a history of pulmonary tuberculosis (1\ub720, 1\ub707-1\ub734; p=0\ub7002), modified Medical Research Council Dyspnoea score (1\ub732, 1\ub725-1\ub739; p<0\ub70001), daily sputum production (1\ub716, 1\ub703-1\ub730; p=0\ub7013), and radiological severity of disease (1\ub703, 1\ub701-1\ub704; p<0\ub70001). Low adherence to guideline-recommended care was observed; only 388 patients were tested for allergic bronchopulmonary aspergillosis and 82 patients had been tested for immunoglobulins. INTERPRETATION: Patients with bronchiectasis in India have more severe disease and have distinct characteristics from those reported in other countries. This study provides a benchmark to improve quality of care for patients with bronchiectasis in India. FUNDING: EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis Consortium, European Respiratory Society, and the British Lung Foundation

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019 : a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dosespecific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in countryreported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings By 2019, global coverage of third-dose DTP (DTP3; 81.6% [95% uncertainty interval 80.4-82 .7]) more than doubled from levels estimated in 1980 (39.9% [37.5-42.1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38.5% [35.4-41.3] in 1980 to 83.6% [82.3-84.8] in 2019). Third- dose polio vaccine (Pol3) coverage also increased, from 42.6% (41.4-44.1) in 1980 to 79.8% (78.4-81.1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56.8 million (52.6-60. 9) to 14.5 million (13.4-15.9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Differential cross section measurements for the production of a W boson in association with jets in proton–proton collisions at √s = 7 TeV

Measurements are reported of differential cross sections for the production of a W boson, which decays into a muon and a neutrino, in association with jets, as a function of several variables, including the transverse momenta (pT) and pseudorapidities of the four leading jets, the scalar sum of jet transverse momenta (HT), and the difference in azimuthal angle between the directions of each jet and the muon. The data sample of pp collisions at a centre-of-mass energy of 7 TeV was collected with the CMS detector at the LHC and corresponds to an integrated luminosity of 5.0 fb[superscript −1]. The measured cross sections are compared to predictions from Monte Carlo generators, MadGraph + pythia and sherpa, and to next-to-leading-order calculations from BlackHat + sherpa. The differential cross sections are found to be in agreement with the predictions, apart from the pT distributions of the leading jets at high pT values, the distributions of the HT at high-HT and low jet multiplicity, and the distribution of the difference in azimuthal angle between the leading jet and the muon at low values.United States. Dept. of EnergyNational Science Foundation (U.S.)Alfred P. Sloan Foundatio